Effects of an appetite suppressant. Subject with preexisting cardiovascular symp

Chaya Galloway 2021-10-25 Answered
Effects of an appetite suppressant. Subject with preexisting cardiovascular symptoms who were receiving sibutramine, an apperite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. The study included 9804 overweight or obese subjects with preexisting cardiovascular disease and/or type 2 diabetes. The subjects were randomly assigned to sibutramine (4906 subjects) or a placebo (4898 subjects) in a double-blind fashion. The primary outcome measured was the occurence of any of the following events: nonfatal myocardial infraction or stroke, resuscitation after cardiac arrest, or cardiovascular death. The primary outcome was observed in 561 subjects in the sibutramine group and 490 subjects in the placebo group.
a) Find the proportion of subjects experiencing the primary outcome for both the sibutramine and placebo groups.
b) Can we safely use the large-sample confidence interval for comparing the proportions of sibutramine and placebo subjects who experienced the primary outcome? Explain.
You can still ask an expert for help

Expert Community at Your Service

  • Live experts 24/7
  • Questions are typically answered in as fast as 30 minutes
  • Personalized clear answers
Learn more

Solve your problem for the price of one coffee

  • Available 24/7
  • Math expert for every subject
  • Pay only if we can solve it
Ask Question

Expert Answer

Laaibah Pitt
Answered 2021-10-26 Author has 98 answers
Step 1
(a) In the survey, out of 4,906 subjects in the sibutramine group of 561 subjects experienced the primary outcome and out of 4,898 subjects in the placebo group of 490 subjects experienced the primary outcome.
The proportion of subjects experiencing the primary outcome for the sibutramine group is,
Psibutramine=5614,906
=0.114
Thus, the proportion of subjects experiencing the primary outcome for the sibutramine group is 0.114.
The proportion of subjects experiencing the primary outcome for the placebo group is,
Pplacebo=4904,898
=0.100
Thus, the proportion of subjects experiencing the primary outcome for the placebo group is 0.100.
Step 2
(b) The general conditions to use the large-sample confidence interval are given below:
Two samples are simple random sample from two distinct populations.
The samples are independent.
Both populations are normally distributed.
The counts of successes and failures are five or more in both the samples.
In the survey, the two samples are randomly selected and independent. Moreover, the counts of successes and failures are larger. Hence, the large-sample confidence interval for comparing the proportions of sibutramine and placebo subjects who experienced the primary outcome can be used safely.
Let p1 denote the proportions of sibutramine subjects who experienced and primary outcome and p2 denote the proportions of placebo subjects who experienced the primary outcome. Here, compute the 95% confidence interval for the difference between the proportions of sibutramine and placebo subjects who experienced primary outcome by using TI-83 graphing calculator.
Confidence interval using TI-83 graphing calculator:
Press STAT>TESTS>2-PropZInt.
Enter x1 as 561, n1 as 4,906, x2 as 490, n2 as 4,898.
C-level: as “0.95”.
Select Calculate and press “Enter”.
Output:
2-PropZInt
(.00207, .02655)
p1=.1143497758
p2=.100040833
n1=4906
n2=4898
From the output, the 95% confidence interval for the difference between the proportions of sibutramine and placebo subjects who experienced the primary outcome is (0.0021,0.0266).
CONCLUDE:
There is 95% confident that the difference between the proportions of sibutramine and placebo subjects who experienced the primary outcome lies between 0.21% and 2.66%.
Not exactly what you’re looking for?
Ask My Question

Expert Community at Your Service

  • Live experts 24/7
  • Questions are typically answered in as fast as 30 minutes
  • Personalized clear answers
Learn more